Physician profile
Thomas D Devine
NPI 1942204508
$5,120.84
in general payments reported to CMS, 2019-2025
38 companies · $952 in 2025
The $952 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $221 · 2021: $74.50 · 2022: $397 · 2023: $908 · 2024: $1,452 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.87 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $832.14 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $603.07 | 2019-2025 | |
| Lilly USA, LLC | $385.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $352.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.64 | 2019-2025 | Jardiance |
| Abbvie INC. | $325.39 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $271.11 | 2023-2024 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $195.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $167.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $139.02 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $124.44 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $118.77 | 2021-2025 | |
| Radius Health, INC. | $107.15 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.18 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $89.85 | 2023-2024 | Gemtesa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.